Minneapolis, MN, June 07, 2016 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a proprietary platform designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used in identifying ablation targets, today announced its submission entitled “Enhanced Electrophysiology Recording System” was accepted as a Late Breaking Research Paper for presentation at the 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC2016).
The conference will be held at the Contemporary Resort in Orlando, Florida August 17 – 20, 2016. The overall theme of the conference is “Empowering Individual Healthcare Decisions through Technology” and will cover diverse topics from cutting-edge biomedical and healthcare technology research and development to clinical applications and biomedical education.
BioSig will have the opportunity to give an oral presentation during the “Ignite” session highlighting the key elements of the PURE EP System and results from the Company’s pre-clinical trials at Mayo Clinic with a poster session to follow.
Commenting on the milestone, Jay Millerhagen VP of Clinical Research said, “We are honored to be approved by the scientific committee for the Late Breaking Research session at the prestigious EMBC 2016 conference and look forward to presenting a technical description of the PURE EP System along with pre-clinical results obtained at Mayo Clinic using our proprietary electrophysiology platform.“
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $4 billion EP marketplace (1) (biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
The PURE EP(TM) System is a surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system engineered to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the electrophysiologists in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1), making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center; has performed pre-clinical studies at Mayo Clinic in Minnesota; and launched an Advanced Research Program at Mayo Clinic in June 2016. The Company is also collaborating with other prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UH Case Medical Center in Cleveland, Ohio and Mount Sinai Medical Center in New York.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
(2) HRI 2013 “Global Opportunities in Medical Devices & Diagnostics” report; triangulation of multiple sources; AF includes left atrial tachycardia, left WPW, left atrial flutter.
About IEEE Engineering in Medicine and Biology Society
IEEE is the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. IEEE and its members inspire a global community to innovate for a better tomorrow through its highly-cited publications, conferences, technology standards, and professional and educational activities. IEEE is the trusted “voice” for engineering, computing and technology information around the globe. Enginering in Medicine and Biology Society (EMBS) is the world’s largest international society of biomedical engineers.
There are more than 420,000 IEEE members in more than 160 countries. IEEE publishes a third of the world’s technical literature in electrical engineering, computer science and electronics and is a leading developer of international standards that underpin many of today’s telecommunications, information technology and power generation products and services.
Contact: Investor Relations: Brian McLaughlin BioSig Technologies, Inc. bmclaughlin@biosigtech.com 917-370-9817
